REYVOW

This brand name is authorized in Japan, United States

Active ingredients

The drug REYVOW contains one active pharmaceutical ingredient (API):

1 Lasmiditan UNII 760I9WM792 - LASMIDITAN

Lasmiditan is a high affinity, centrally-penetrant, 5-hydroxytriptamine 1F (5-HT1F) receptor agonist. The precise mechanism of action is unknown, however, the therapeutic effects of lasmiditan in the treatment of migraine presumably involve agonistic effects at the 5-HT1F receptor, a decrease of neuropeptide release and an inhibition of pain pathways, including the trigeminal nerve. Read about Lasmiditan

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
REYVOW Tablet	FDA, National Drug Code (US)	MPI, US: SPL/PLR

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
N02CC08		N Nervous system → N02 Analgesics → N02C Antimigraine preparations → N02CC Selective serotonin (5HT1) agonists
Discover more medicines within N02CC08

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: JP	医薬品医療機器総合機構	Identifier(s): 1190030F1024, 1190030F2020
Country: US	FDA, National Drug Code	Identifier(s): 0002-4312, 0002-4491